Atavistik Bio is a new, privately-held biopharmaceutical company focused on the discovery and development of novel therapies for metabolic diseases and cancer. Our high-throughput platform for the unbiased identification of metabolite-protein interactions will enable the discovery of first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems to apply to genetically validated targets.
Location: United States
Employees: 11-50
Total raised: $220M
Founded date: 2021
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.12.2025 | Series B | $120M | Nextech In... |
| 22.12.2023 | - | $40M | - |
| 24.08.2021 | Series A | $60M | - |
Mentions in press and media 16
| Date | Title | Description |
| 11.08.2026 | ‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder | Vaderis Therapeutics has secured an oversubscribed $152 million series B financing to propel the Swiss biotech's AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rare blood vessel disorder to market. The Base... |
| 28.12.2025 | Atavistik Bio Secures $120 Million: Advancing Precision Therapies for HHT and MPNs | Atavistik Bio secured $120 million in Series B funding. This substantial capital will advance two crucial therapeutic programs. An oral AKT1-selective inhibitor targets Hereditary Hemorrhagic Telangiectasia (HHT). A JAK2 V617F mutant-select... |
| 27.12.2025 | Atavistik Bio: $120 Million Series B Raised To Advance Selective Allosteric Small-Molecule Programs In HHT And MPNs | Atavistik Bio announced it raised a $120 million Series B financing to push two selective allosteric small-molecule programs into clinical proof-of-concept studies: an oral, AKT1-selective allosteric inhibitor for hereditary hemorrhagic tel... |
| 21.12.2025 | Atavistik Bio Raises $120M in Series B Financing | Atavistik Bio, a Cambridge, MA-based developer of selective allosteric small molecule therapeutics, raised $120m in Series B financing. The round was led by Nextech Invest and The Column Group with participation from Lux Capital and new inv... |
| 21.12.2025 | HBox Receives Growth Investment from Charlesbank Capital Partners | HBox, a Boston, Massachusetts-based developer of a virtual care platform for specialty practices, raised a strategic growth investment from Charlesbank Technology Opportunities Fund II. The amount of the deal was not disclosed. The company ... |
| 18.12.2025 | Top Startup and Tech Funding News – December 18, 2025 | It’s Thursday, December 18, 2025, and we’re back with today’s top startup and tech funding news spanning AI software development, biotech, industrial engineering, and embedded cybersecurity. From early-stage compliance automation to mega-ro... |
| 22.12.2023 | Atavistik Bio Raises Additional $40M in Funding | Atavistik Bio, a Cambridge, MA-based biotechnology company discovering precision allosteric therapeutics, raised additional $40M in funding. The round saw participation from The Column Group, Lux Capital, and Nextech Invest. The company int... |
| 19.12.2023 | Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics | - |
| 19.12.2023 | Atavistik Bio Lands Additional $40M | CAMBRIDGE, MA, Atavistik Bio today announced that it has raised an additional $40 million in funding. >> Click here for more funding data on Atavistik Bio >> To export Atavistik Bio funding data to PDF and Excel, click here ... |
| 10.01.2023 | Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics | Proprietary AMPS platform enables the systematic and rapid interrogation of protein-metabolite interactions to reveal new, disease-relevant allosteric binding sites Atavistik Bio, a biotechnology company focused on revolutionizing the disco... |
Show more